141 related articles for article (PubMed ID: 26237292)
1. Molecular biomarkers in colorectal carcinoma.
Puerta-García E; Cañadas-Garre M; Calleja-Hernández MÁ
Pharmacogenomics; 2015; 16(10):1189-222. PubMed ID: 26237292
[TBL] [Abstract][Full Text] [Related]
2. Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer.
Carethers JM; Jung BH
Gastroenterology; 2015 Oct; 149(5):1177-1190.e3. PubMed ID: 26216840
[TBL] [Abstract][Full Text] [Related]
3. Molecular Diagnostics in Colorectal Carcinoma: Advances and Applications for 2018.
Bhalla A; Zulfiqar M; Bluth MH
Clin Lab Med; 2018 Jun; 38(2):311-342. PubMed ID: 29776633
[TBL] [Abstract][Full Text] [Related]
4. DNA methylation markers in colorectal cancer.
Kim MS; Lee J; Sidransky D
Cancer Metastasis Rev; 2010 Mar; 29(1):181-206. PubMed ID: 20135198
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-31 expression in relation to BRAF mutation, CpG island methylation and colorectal continuum in serrated lesions.
Ito M; Mitsuhashi K; Igarashi H; Nosho K; Naito T; Yoshii S; Takahashi H; Fujita M; Sukawa Y; Yamamoto E; Takahashi T; Adachi Y; Nojima M; Sasaki Y; Tokino T; Baba Y; Maruyama R; Suzuki H; Imai K; Yamamoto H; Shinomura Y
Int J Cancer; 2014 Dec; 135(11):2507-15. PubMed ID: 24752710
[TBL] [Abstract][Full Text] [Related]
6. Application of molecular techniques in the diagnosis, prognosis and management of patients with colorectal cancer: a practical approach.
Legolvan MP; Taliano RJ; Resnick MB
Hum Pathol; 2012 Aug; 43(8):1157-68. PubMed ID: 22658275
[TBL] [Abstract][Full Text] [Related]
7. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer.
Goel A; Nagasaka T; Arnold CN; Inoue T; Hamilton C; Niedzwiecki D; Compton C; Mayer RJ; Goldberg R; Bertagnolli MM; Boland CR
Gastroenterology; 2007 Jan; 132(1):127-38. PubMed ID: 17087942
[TBL] [Abstract][Full Text] [Related]
8. Focus on genetic and epigenetic events of colorectal cancer pathogenesis: implications for molecular diagnosis.
Zoratto F; Rossi L; Verrico M; Papa A; Basso E; Zullo A; Tomao L; Romiti A; Lo Russo G; Tomao S
Tumour Biol; 2014 Jul; 35(7):6195-206. PubMed ID: 25051912
[TBL] [Abstract][Full Text] [Related]
9. Targeting aberrant chromatin structure in colorectal carcinomas.
Konishi K; Issa JP
Cancer J; 2007; 13(1):49-55. PubMed ID: 17464246
[TBL] [Abstract][Full Text] [Related]
10. CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer.
Cleven AH; Derks S; Draht MX; Smits KM; Melotte V; Van Neste L; Tournier B; Jooste V; Chapusot C; Weijenberg MP; Herman JG; de Bruïne AP; van Engeland M
Clin Cancer Res; 2014 Jun; 20(12):3261-71. PubMed ID: 24928946
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers in Colorectal Cancer.
Yiu AJ; Yiu CY
Anticancer Res; 2016 Mar; 36(3):1093-102. PubMed ID: 26977004
[TBL] [Abstract][Full Text] [Related]
12. DNA methylation biomarkers as diagnostic and prognostic tools in colorectal cancer.
Gyparaki MT; Basdra EK; Papavassiliou AG
J Mol Med (Berl); 2013 Nov; 91(11):1249-56. PubMed ID: 24057814
[TBL] [Abstract][Full Text] [Related]
13. Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype.
Ogino S; Kawasaki T; Ogawa A; Kirkner GJ; Loda M; Fuchs CS
Hum Pathol; 2007 Jun; 38(6):842-9. PubMed ID: 17350669
[TBL] [Abstract][Full Text] [Related]
14. Important molecular genetic markers of colorectal cancer.
Kudryavtseva AV; Lipatova AV; Zaretsky AR; Moskalev AA; Fedorova MS; Rasskazova AS; Shibukhova GA; Snezhkina AV; Kaprin AD; Alekseev BY; Dmitriev AA; Krasnov GS
Oncotarget; 2016 Aug; 7(33):53959-53983. PubMed ID: 27276710
[TBL] [Abstract][Full Text] [Related]
15. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.
Han SW; Lee HJ; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
Int J Cancer; 2013 May; 132(9):2209-16. PubMed ID: 23034738
[TBL] [Abstract][Full Text] [Related]
16. Are clinicopathological features of colorectal cancers with methylation in half of CpG island methylator phenotype panel markers different from those of CpG island methylator phenotype-high colorectal cancers?
Bae JM; Rhee YY; Kim KJ; Wen X; Song YS; Cho NY; Kim JH; Kang GH
Hum Pathol; 2016 Jan; 47(1):85-94. PubMed ID: 26520418
[TBL] [Abstract][Full Text] [Related]
17. Molecular evolution of colorectal cancer: from multistep carcinogenesis to the big bang.
Amaro A; Chiara S; Pfeffer U
Cancer Metastasis Rev; 2016 Mar; 35(1):63-74. PubMed ID: 26947218
[TBL] [Abstract][Full Text] [Related]
18. Colorectal poorly differentiated neuroendocrine carcinomas frequently exhibit BRAF mutations and are associated with poor overall survival.
Olevian DC; Nikiforova MN; Chiosea S; Sun W; Bahary N; Kuan SF; Pai RK
Hum Pathol; 2016 Mar; 49():124-34. PubMed ID: 26826419
[TBL] [Abstract][Full Text] [Related]
19. BRAF mutation, CpG island methylator phenotype and microsatellite instability occur more frequently and concordantly in mucinous than non-mucinous colorectal cancer.
Tanaka H; Deng G; Matsuzaki K; Kakar S; Kim GE; Miura S; Sleisenger MH; Kim YS
Int J Cancer; 2006 Jun; 118(11):2765-71. PubMed ID: 16381005
[TBL] [Abstract][Full Text] [Related]
20. The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status.
Dahlin AM; Palmqvist R; Henriksson ML; Jacobsson M; Eklöf V; Rutegård J; Oberg A; Van Guelpen BR
Clin Cancer Res; 2010 Mar; 16(6):1845-55. PubMed ID: 20197478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
